Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- carboplatin
- MSP-Blu (hyoscyamine / methenamine / methylene blue / phenyl salicylate)
Interactions between your drugs
CARBOplatin phenyl salicylate
Applies to: carboplatin, MSP-Blu (hyoscyamine / methenamine / methylene blue / phenyl salicylate)
MONITOR: Coadministration of carboplatin with other nephrotoxic agents may increase the risk of renal impairment due to additive effects on the kidney. Moreover, renal impairment secondary to the use of these agents may reduce the clearance of carboplatin, which is primarily eliminated by renal excretion. This may increase the risk of other adverse effects including severe myelosuppression which is concentration-dependent. Approximately 25% of patients receiving carboplatin exhibit decreases in creatinine clearance, whereas rises in serum creatinine and blood urea nitrogen occur less frequently. Some data suggests hypomagnesemia is the primary indicator of carboplatin-induced nephrotoxicity. Patients receiving multiple courses or single doses exceeding 800 mg/m2 of carboplatin, or those with a history of cisplatin-induced nephrotoxicity, may be at increased risk of renal toxicity.
MANAGEMENT: Renal function and serum magnesium levels should be monitored if carboplatin is used concomitantly with other nephrotoxic agents. The potential for increased toxicity of carboplatin such as peripheral sensory neuropathies and myelosuppression should be considered.
References (7)
- (2024) "Product Information. Carboplatin (CARBOplatin)." Apotex Corporation
- (2024) "Product Information. Carboplatin (CARBOplatin)." Accord Healthcare
- (2024) "Product Information. Carboplatin (carboplatin)." Pfizer Ltd
- (2024) "Product Information. cARBOplatin (Accord) (cARBOplatin)." Accord Healthcare Pty Ltd
- Malyszko J, Kozlowska K, Kozlowski LM, Malyszko JS (2017) "Nephrotoxicity of anticancer treatment." Nephrol Dial Transplant, 32, p. 924-36
- english mw, Skinner R, pearson adj, wyllie r, Craft AW (1999) "Dose-related nephrotoxicity of carboplatin in children." Br J Cancer, 81, p. 336-41
- Sleijfer DT, smit ef, Meijer S, Mulder NH, postmus pe (1989) "Acute and cumulative effects of carboplatin on renal function." Br J Cancer, 60, p. 116-20
Drug and food/lifestyle interactions
hyoscyamine food/lifestyle
Applies to: MSP-Blu (hyoscyamine / methenamine / methylene blue / phenyl salicylate)
GENERALLY AVOID: Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous. In addition, the potential for abuse may be increased with the combination. The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system. No effect of oral propantheline or atropine on blood alcohol levels was observed in healthy volunteers when administered before ingestion of a standard ethanol load. However, one study found impairment of attention in subjects given atropine 0.5 mg or glycopyrrolate 1 mg in combination with alcohol.
MANAGEMENT: Alcohol should generally be avoided during therapy with anticholinergic agents. Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.
References (1)
- Linnoila M (1973) "Drug effects on psychomotor skills related to driving: interaction of atropine, glycopyrrhonium and alcohol." Eur J Clin Pharmacol, 6, p. 107-12
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Keytruda
Keytruda is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma ...
Avastin
Avastin is used to brain tumors and cancers of the kidney, colon, rectum, or lung. Learn about side ...
Botox
Botox is used cosmetically to reduce facial lines and wrinkles and for medical purposes for ...
Taxol
Taxol (paclitaxel) is used to treat breast cancer, lung cancer, and ovarian cancer. Includes Taxol ...
Lynparza
Lynparza (olaparib) is used to treat ovarian cancer, breast cancer, pancreatic cancer, and prostate ...
Gemcitabine
Gemcitabine is used for breast cancer, breast cancer, metastatic, nasopharyngeal carcinoma, non ...
Paclitaxel
Paclitaxel is used for breast cancer, breast cancer, adjuvant, breast cancer, metastatic, kaposi's ...
Bevacizumab
Bevacizumab injection is a targeted cancer drug used to treat types of non-small cell lung cancer ...
Doxorubicin
Doxorubicin is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder cancer ...
Cyclophosphamide
Cyclophosphamide is used for acute lymphocytic leukemia, acute nonlymphocytic leukemia, brain ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.